- Podcast - IR Department talks with AdAlta CEO & MD, Dr Tim Oldham
- IRD Invest March 2022 - Openpay
- IRD Invest March 2022 - Oventus
- IRD Invest March 2022 - Pureprofile
- Register now for our next IRD Invest virtual investor conference, where emerging tech companies will talk about the tailwinds driving their businesses
Surge in growth stocks lifts investor relations activity
2021 has been a record year for the number of initial public offerings (IPOs), with more than 130 on the ASX so far and dozens more anticipated by the end of December. The heightened IPO activity was fuelled by strong investor demand across a broad range of sectors. Led by resources, healthcare and technology stocks, it’s been the biggest global IPO surge in more than 20 years.
What will investors be looking out for this reporting period?
With another financial reporting season upon us, we thought it an opportune time to consider what the investment community will likely be focusing on as they contemplate how best to position their portfolios over the next 6-12 months.
The evolution of social media in crisis communications – Part One: Pre-crisis planning
In the world of issues and crisis management, today’s landscape is dramatically different to that of just a few years ago. Today we are living in a society of digitally enabled, always-on, constantly connected consumers with a multitude of smart devices at their fingertips.
Tesserent presents at IRD Invest
On 14 October 2020, Tesserent CEO, Julian Challingsworth presented at IR Department’s virtual investor conference, IRD Invest, an event designed to bring investors directly to the CEOs of emerging ASX listed companies.
Oventus presents at IRD Invest
On 14 October 2020, Oventus CEO, Dr Chris Hart, presented at IR Department’s virtual investor conference, IRD Invest, an event designed to bring investors directly to the CEOs of emerging ASX listed companies.
Kazia achieves major milestones
Our client, ASX-listed oncology company Kazia Therapeutics Ltd (ASX: KZA; NASDAQ: KZIA, has had a huge few months, including the achievement of significant milestones for lead drug candidate, paxalisib.
All set for your AGM?
We're all starting to think about AGMs (in fact, the IR Department team has already supported clients through a few! As companies are often running virtual AGMs for the first time this year, our friends at IRM have put together some thoughts on the corporate website can be a great tool to support shareholders with understanding how to join and vote. Thanks to the team at IRM for allowing us to share this post.